Abstract
The Zika virus (ZIKV) epidemic has resulted in congenital abnormalities in fetuses and neonates. Although some cross-reactive dengue virus (DENV)-specific antibodies can enhance ZIKV infection in mice, those recognizing the DENV E-dimer epitope (EDE) can neutralize ZIKV infection in cell culture. We evaluated the therapeutic activity of human monoclonal antibodies to DENV EDE for their ability to control ZIKV infection in the brains, testes, placentas, and fetuses of mice. A single dose of the EDE1-B10 antibody given 3 d after ZIKV infection protected against lethality, reduced ZIKV levels in brains and testes, and preserved sperm counts. In pregnant mice, wild-type or engineered LALA variants of EDE1-B10, which cannot engage Fcg receptors, diminished ZIKV burden in maternal and fetal tissues, and protected against fetal demise. Because neutralizing antibodies to EDE have therapeutic potential against ZIKV, in addition to their established inhibitory effects against DENV, it may be possible to develop therapies that control disease caused by both viruses.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Weaver, S.C. et al. Zika virus: History, emergence, biology, and prospects for control. Antiviral Res. 130, 69–80 (2016).
Brasil, P. et al. Zika virus infection in pregnant women in Rio de Janeiro. N. Engl. J. Med. 375, 2321–2334 (2016).
Schaub, B. et al. Analysis of blood from Zika-virus-infected fetuses: a prospective case series. Lancet Infect. Dis. 3099, 26–28 (2017).
Honein, M.A. et al. Birth defects among fetuses and infants of US women with evidence of possible Zika virus infection during pregnancy. J. Am. Med. Assoc. 317, 59–68 (2017).
Cao-Lormeau, V.-M. et al. Guillain–Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case–control study. Lancet 387, 1531–1539 (2016).
Parra, B. et al. Guillain–Barré Syndrome associated with Zika virus infection in Colombia. N. Engl. J. Med. 375, 1513–1523 (2016).
Dai, L. et al. Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody. Cell Host Microbe 19, 696–704 (2016).
Kuhn, R.J. et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108, 717–725 (2002).
Dowd, K.A. et al. Broadly neutralizing activity of Zika-virus-immune sera identifies a single viral serotype. Cell Rep. 16, 1485–1491.
Barba-Spaeth, G. et al. Structural basis of potent Zika–dengue virus antibody cross-neutralization. Nature 536, 48–53 (2016).
Dejnirattisai, W. et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat. Immunol. 16, 170–177 (2015).
Fernandez, E. & Diamond, M.S. Vaccination strategies against Zika virus. Curr. Opin. Virol. 23, 59–67 (2017).
Nelson, S. et al. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog. 4, e1000060 (2008).
Kam, Y.-W. et al. Cross-reactive dengue human monoclonal antibody prevents severe pathologies and death from Zika virus infections. JCI Insight 2, http://dx.doi.org/10.1172/jci.insight.92428 (2017).
Halstead, S.B., Mahalingam, S., Marovich, M.A., Ubol, S. & Mosser, D.M. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect. Dis. 10, 712–722 (2010).
Dejnirattisai, W. et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus. Nat. Immunol. 17, 1102–1108 (2016).
Stettler, K. et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 353, 823–826 (2016).
Zhao, H. et al. Structural basis of Zika-virus-specific antibody protection. Cell 166, 1016–1027 (2016).
Sapparapu, G. et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature 540, 443–447 (2016).
Robbiani, D.F. et al. Recurrent potent human neutralizing antibodies to Zika virus in Brazil and Mexico. Cell 169, 597–609 (2017).
Wang, Q. et al. Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Sci. Transl. Med. 8, 369ra179 (2016).
Swanstrom, J.A. et al. Dengue virus envelope dimer epitope monoclonal antibodies isolated from dengue patients are protective against Zika virus. MBio 7, e01123–e16 (2016).
Hirsch, A.J. et al. Zika virus infection of rhesus macaques leads to viral persistence in multiple tissues. PLoS Pathog. 13, e1006219 (2017).
Miner, J.J. et al. Zika Virus infection in mice causes panuveitis with shedding of virus in tears. Cell Rep. 16, 3208–3218 (2016).
Bhatnagar, J. et al. Zika virus RNA replication and persistence in brain and placental tissue. Emerg. Infect. Dis. 23, 405–414 (2017).
Aid, M. et al. Zika virus persistence in the central nervous system and lymph nodes of rhesus monkeys. Cell 169, 610–620 (2017).
Govero, J. et al. Zika virus infection damages the testes in mice. Nature 540, 438–442 (2016).
Ma, W. et al. Zika virus causes testis damage and leads to male infertility in mice. Cell 167, 1511–1524 (2016).
Yockey, L.J. et al. Vaginal exposure to Zika virus during pregnancy leads to fetal brain infection. Cell 166, 1247–1256 (2016).
Rouvinski, A. et al. Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope. Nat. Commun. 8, 15411 (2017).
Pierson, T.C. & Diamond, M.S. A game of numbers: the stoichiometry of antibody-mediated neutralization of flavivirus infection. Prog. Mol. Biol. Transl. Sci. 129, 141–166 (2015).
Hessell, A.J. et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101–104 (2007).
Magdelaine-Beuzelin, C., Pinault, C., Paintaud, G. & Watier, H. Therapeutic antibodies in ophthalmology: old is new again. MAbs 2, 176–180 (2010).
Miner, J.J. et al. Zika virus infection during pregnancy in mice causes placental damage and fetal demise. Cell 165, 1081–1091 (2016).
Cugola, F.R. et al. The Brazilian Zika virus strain causes birth defects in experimental models. Nature 534, 267–271 (2016).
Foy, B.D. et al. Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerg. Infect. Dis. 17, 880–882 (2011).
Musso, D. et al. Potential sexual transmission of Zika virus. Emerg. Infect. Dis. 21, 359–361 (2015).
Russell, K. et al. Male-to-female sexual transmission of Zika virus—United States, January–April 2016. Clin. Infect. Dis. 64, 211–213 (2017).
Davidson, A., Slavinski, S., Komoto, K., Rakeman, J. & Weiss, D. Suspected female-to-male sexual transmission of Zika virus—New York City, 2016. MMWR Morb. Mortal. Wkly. Rep. 65, 716–717 (2016).
Deckard, D.T. et al. Male-to-male sexual transmission of Zika virus—Texas, January 2016. MMWR Morb. Mortal. Wkly. Rep. 65, 372–374 (2016).
Barzon, L. et al. Infection dynamics in a traveller with persistent shedding of Zika virus RNA in semen for six months after returning from Haiti to Italy, January 2016. Euro Surveill. 21, 30316 (2016).
Richner, J.M. et al. Vaccine-mediated protection against Zika-virus-induced congenital disease. Cell 170, 273–283 (2017).
Sukupolvi-Petty, S. et al. Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J. Virol. 87, 8826–8842 (2013).
Mansuy, J.M. et al. Zika virus: high infectious viral load in semen, a new sexually transmitted pathogen? Lancet Infect. Dis. 16, 405 (2016).
Murray, K.O. et al. Prolonged detection of Zika virus in vaginal secretions and whole blood. Emerg. Infect. Dis. 23, 99–101 (2017).
Zeitlin, L. et al. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc. Natl. Acad. Sci. USA 108, 20690–20694 (2011).
DiLillo, D.J., Tan, G.S., Palese, P. & Ravetch, J.V. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat. Med. 20, 143–151 (2014).
Hiatt, A. et al. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc. Natl. Acad. Sci. USA 111, 5992–5997 (2014).
Carroll, T. et al. Zika virus preferentially replicates in the female reproductive tract after vaginal inoculation of rhesus macaques. PLoS Pathog. 13, e1006537 (2017).
Halstead, S.B. Biologic evidence required for Zika disease enhancement by dengue antibodies. Emerg. Infect. Dis. 23, 569–573 (2017).
Brien, J.D., Lazear, H.M. & Diamond, M.S. Propagation, quantification, detection, and storage of West Nile virus. Curr. Protoc. Microbiol. 31, 15D.3.1–15D.3.18 (2013).
National Research Council. Guide for the Care and Use of Laboratory Animals 8th edn. (The National Academies Press, 2011).
Lanciotti, R.S. et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg. Infect. Dis. 14, 1232–1239 (2008).
Hansen, D.A., Esakky, P., Drury, A., Lamb, L. & Moley, K.H. The aryl hydrocarbon receptor is important for proper seminiferous tubule architecture and sperm development in mice. Biol. Reprod. 90, 8 (2014).
Goodson, S.G., Zhang, Z., Tsuruta, J.K., Wang, W. & O'Brien, D.A. Classification of mouse sperm motility patterns using an automated multiclass support vector machines model. Biol. Reprod. 84, 1207–1215 (2011).
Acknowledgements
We thank Haina Shin for advice on the intravaginal infection experiments, S. Whitehead (US National Institutes of Health (NIH)) for ZIKV-Brazil (Paraiba, 2015), S. Shresta(La Jolla Institute of Allergy and Immunology) for DENV-2 strain D2S20, P. Malasit and S. Noisakran (Mahidol University) for DENV-1, DENV-3, and DENV-4 isolates from patients, C. Simmons (University of Melbourne) for DENV-2 strain DF-699, A. Kohl, R.F. de Oliveira Freitas, and L.J. Pena (University of Glasgow) for ZIKV-Brazil PE243, and A. Sakuntabhai (Institut Pasteur) for ZIKV-Africa HD78788. Supported by grants and contracts from the NIH (R01 AI073755 (M.S.D.), R01 AI127828 (M.S.D.), R01 HD091218 (I.U.M. and M.S.D.), HHSN272201400018C (M.S.D.), T32 AI007163 (E.F.)), the Wellcome Trust (G.R.S.), MRC-NEWTON UK (J.M.), and the National Institute for Health Research Biomedical Research Centre funding scheme UK (G.R.S.).
Author information
Authors and Affiliations
Contributions
E.F., J.M., W.D., S.M.S., B.C., G.R.S., and M.S.D. designed the experiments; E.F., W.D., S.M.S., B.C., P.S., and W.W. performed the experiments; E.F., J.M., W.D., S.M.S., B.C., P.E., A.D., I.U.M., K.H.M., G.R.S., and M.S.D. analyzed the data; E.F. and M.S.D. wrote the first draft of the paper; and all authors participated in editing the final version of the manuscript.
Corresponding authors
Ethics declarations
Competing interests
M.S.D. is a consultant for Inbios, Visterra, Aviana and Sanofi-Pasteur and is on the Scientific Advisory Boards of Moderna and OvaGene. G.R.S. is on the Vaccine Scientific Advisory Board of GlaxoSmithKline plc.
Integrated supplementary information
Supplementary Figure 1 EDE-specific mAbs protect against ZIKV-induced lethality.
Four to five week-old WT male mice were treated with anti-Ifnar1 mAb followed by subcutaneous infection with 103 FFU of mouse-adapted ZIKV-Dakar. Mice then were treated with isotype-control, EDE1-C8, or EDE2-A11 mAbs at day +1 (100 μg, left) or day +3 (250 μg, right). Data were pooled from two (isotype-control mAb) or three (EDE1-C8 and EDE2-A11) independent experiments (isotype-control mAb, n = 19; EDE1-C8, n = 10; EDE2-A11, n = 10). Statistical significance was analyzed (log-rank test: ****, P < 0.0001).
Supplementary Figure 2 Levels of EDE1-B10 mAb in tissues at day +5 after infection.
Eight to nine week old WT male mice were treated with a single dose of EDE1-B10 mAb at day +1 or +3 as described in Fig 2. a. At D+5, tissues were harvested and EDE1-B10 levels were assessed by ELISA using a standard curve. Bars indicate median values. Data were pooled from two independent experiments, and symbols correspond to individual mice (n = 8 per group). Statistical analysis was determined (Mann-Whitney test: **, P < 0.01; ***, P < 0.001).
Supplementary Figure 3 ISH and histological analysis of epididymis from mice treated with EDE1-B10.
Eight- to nine- week old male WT mice were treated with isotype control or EDE1-B10 mAb at day +1 (n=6 mice), day +3 (n=4 mice), day +5 (n=8 mice) after infection, as described in Figure 2. a. RNA in situ hybridization (ISH) staining of epididymis at day +21 using ZIKV-specific RNA probes. Low power (scale bar = 500 μm) and high power (scale bar = 20 μm) images are presented in sequence. The images in the panels are representative of sections from 4 to 6 mice. b. H & E staining of epididymis. Low power (scale bar = 500 μm) and high power (scale bar = 20 μm) images are shown in sequence. The images are representative of sections from 3 to 5 mice.
Supplementary Figure 4 Protection of pregnant mice with WT and LALA EDE1-C8 mAbs.
WT female mice were mated with WT sires. At E5.5, dams were treated with anti-Ifnar1 mAb. At E6.5, dams were infected subcutaneously with 103 FFU of mouse-adapted ZIKV-Dakar. At E7.5 (day +1), dams were treated with 250 μg of either isotype-control mAb or EDE1-C8 (wild-type or LALA variant). At E13.5, placentas and fetal heads were harvested, and viral RNA was assessed by qRT-PCR. Bars indicate median values. Data were pooled from two independent experiments, and symbols correspond to individual mice (isotype mAb, n = 16; EDE1-C8, n = 20; EDE1-C8 LALA, n = 12). Statistical significance was determined (Kruskal-Wallis test: ***, P < 0.001; ****, P < 0.0001). Dashed line indicates the limit of detection for the assay.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–4. (PDF 560 kb)
Rights and permissions
About this article
Cite this article
Fernandez, E., Dejnirattisai, W., Cao, B. et al. Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection. Nat Immunol 18, 1261–1269 (2017). https://doi.org/10.1038/ni.3849
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ni.3849
This article is cited by
-
The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86
Nature Communications (2024)
-
Recombinant Protein Mimicking the Antigenic Structure of the Viral Surface Envelope Protein Reinforces Induction of an Antigen-Specific and Virus-Neutralizing Immune Response Against Dengue Virus
Journal of Microbiology (2023)
-
Protective Zika vaccines engineered to eliminate enhancement of dengue infection via immunodominance switch
Nature Immunology (2021)
-
Competitive ELISA for a serologic test to detect dengue serotype-specific anti-NS1 IgGs using high-affinity UB-DNA aptamers
Scientific Reports (2021)
-
The continued threat of emerging flaviviruses
Nature Microbiology (2020)